KALAMAZOO ? The first Kalamazoo Venture Tuesday of 2005 will feature presentations from a company making a high-tech grease trap, another making a DNA cancer treatment, and a third making a bio-Respirator mask.

First Tuesday is a monthly morning meeting that is part of Southwest Michigan First’s Investing In Innovation Forum series. Venture Tuesday provides informal networking among entrepreneurs, investors, and others interested in developing entrepreneurship in Michigan and the Great Lakes region.

The next scheduled Kalamazoo Venture Tuesday is Jan. 4 from 9 to 11 a.m. at the Southwest Michigan Innovation Center.

Presenting will be:

PMC Environmental Technologies – PMC?s BIOS GT is a patent-pending biological reactor that achieves heretofore-unachievable FOG reduction results by continuously controlling an environment of FOG-eating microbes. The BIOS GT system monitors input and output conditions, and constantly adjusts temperature, aeration, mixing, and other factors within the reactor to ensure reliable and predictable performance. The BIOS GT system features on-site displays of performance and functions, and can be remotely monitored for quality control. The BIOS GT system can be installed as a new system in place of a grease trap or as a retrofit to an existing grease trap.

Immune Cell Therapy – is a new biotechnology company developing autologous (“patient-individualized”) DNA-based cancer vaccines for metastatic cancer. Immune Cell’s platform technology, called Met-VAX, was developed at the University of Illinois-Chicago by renowned tumor immunologist Dr. Edward P. Cohen, and has been evaluated in preclinical models for several types of cancer including head & neck, breast, melanoma and brain. Immune Cell Therapy is looking to begin its first phase I clinical trial in 2005.”

Lincoln Advanced Technologies – is a development stage producer of health and safety equipment for government, industry, and the ?critical infrastructure? segments of the US economy. Lincoln?s first product is a patent-pending innovation called the Extended-wear BioRespirator Mask, or EBR. The EBR prevents the transmission of respiratory-based infectious diseases including SARS, Avian flu and the most likely pathogens expected to be used as biological weapons by using a proprietary filtering technology to eliminate bacteria and viruses from respiration and by cutting off the supply of dirty air recirculation.

Admission is free, but pre-registration is required. Email contact information to Gail Lindsey at [email protected]. If you are interested in presenting at a future meeting, please contact Lori Wolfe [email protected] (269) 337.7350.